logo-loader
HealthPharma & Biotech
MaxCyte

MaxCyte pre-clinical data shows correction of sickle cell disease mutation

Pre-clinical data presented Friday (May 18) at an industry assessed the use of non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder

1526885000_shutterstock_255595165.jpg
Sickle cell is a blood disorder

MaxCyte Inc's (LON:MXCT) technology may have a role to play in the treatment of sickle cell disease (SCD).

Pre-clinical data presented Friday (May 18) at an industry assessed the use of  non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder.

The data from work with the National Institutes of Health's National Heart Lung and Blood Institute demonstrated the potential of MaxCyte's technologies and the non-viral CRISPR gene correction in the treatment of SCD.

READ: The abstract here 

Delegates at the American Society of Gene and Cell Therapy, held in Chicago, were provided the information in a poster.

The company's chief executive, Doug Doerfler, said: "We're encouraged that MaxCyte's technology is at the forefront of enabling non-viral  CRISPR-mediated correction of disease mutations at clinically-relevant levels.

"We're excited by these results for their potential to bring therapeutic benefit to individuals living with SCD."

 

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £69.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read